Outcome of Board Meeting held on 21st May 2026
SUDEEPPHRM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sudeep Pharma's Board approved audited FY26 consolidated results showing strong performance with revenue from operations growing 28% to Rs. 64,225.80 lakhs from Rs. 50,199.92 lakhs in FY25. Profit after tax rose 25.6% to Rs. 17,428.47 lakhs, with EPS improving from Rs. 12.79 to Rs. 15.50. The Board recommended a final dividend of Rs. 1.50 per share (150% on Rs. 1 face value). The company completed its IPO in November 2025 raising Rs. 8,833.59 lakhs net proceeds, and acquired Nutrition Supplier & Services (Ireland) Limited as a step-down subsidiary in May 2025. Auditors BSR and Co issued an unmodified (clean) opinion on both standalone and consolidated results.
Strong financial growth with 25%+ PAT growth signals solid operational performance. The company operates in two segments (Pharmaceutical/Food/Nutrition and Speciality Ingredients) both contributing to revenue. The clean audit opinion and dividend recommendation are positive signals for shareholders.